QURE News and Press, uniQure N.V. From 08/01/23

2023-08-01 08:01:18 ET uniQure press release ( NASDAQ: QURE ): Q2 EPS of -$1.44 may not be comparable to consensus of $2.72. Revenue of $2.4M (+380.0% Y/Y). Revenue for the three months ended June 30, 2023 was $2.4 million, compared to $0.5 million in the same period i...

~ Announced encouraging interim analysis data from ongoing Phase I/II clinical trial of AMT-130 in Huntington’s disease showing preservation of function compared to baseline and clinical benefits relative to natural history; both dose cohorts of AMT-130 continue to be generally well-tolera...

2023-07-17 13:47:20 ET Summary AMT-130, a gene therapy designed to inhibit the production of mutant huntingtin protein, has shown perplexing results in trials. The safety profile of AMT-130 is acceptable and further data is expected in Q4. Despite the confusing data, there are...

LEXINGTON, Mass. and AMSTERDAM, June 26, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Walid Abi-Saab, M.D., as Chief Medical Officer, effective...

2023-06-22 15:03:58 ET Shares of gene therapy specialist uniQure (NASDAQ: QURE) fell by 42% during the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence . The stock's big weekly loss stems from a mixed interim anal...

2023-06-21 13:20:27 ET Gainers: Argo Blockchain ( ARBK ) +32% . Ocean Biomedical ( OCEA ) +21% . Mullen Automotive ( MULN ) +20% . Freightos Limited ( CRGO ) +18% . PureCycle Technologies ( PCT ) +17% . PetVivo Holdings ( P...

2023-06-21 10:07:44 ET Gainers: Ocean Biomedical ( OCEA ) +43% . PetVivo Holdings ( PETV ) +23% . Patterson Companies ( PDCO ) +14% . Zentalis Pharmaceuticals ( ZNTL ) +5% . RenovoRx ( RNXT ) +4% . Losers: uniQure ( ...

2023-06-21 08:24:41 ET Dutch biotech uniQure N.V. ( NASDAQ: QURE ) fell ~30% pre-market Wednesday after announcing interim data from its Phase 1/2 trial for AMT-130 in the treatment of neurogenerative disorder Huntington’s disease. Citing up to 24 months of follow-up ...

2023-06-21 08:14:39 ET uniQure ( QURE ) -29% announces update on U.S. phase I/II clinical trial of AMT-130 gene therapy for the treatment of huntington’s disease . VCI Global Limited ( VCIG ) -20% . Red Cat Holdings ( RCAT ) -13% . voxeljet (...

~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural history of the disease ~ ~ Neurofilament Light Chain (NfL) in cerebrospinal fluid ...